How to buy Humacyte, Inc. stock on Stash
- Enter the amount you'd like to invest in Humacyte, Inc. stock, then proceed to checkout. Stash allows you to purchase...
- Choose a Stash plan and set up your investment account in just a few minutes. Stash offers three subscription plans:...
- Once you’ve finished your account, your Humacyte, Inc. shares will be added to...
Full Answer
How much of Humacyte's stock are insiders selling?
In the past three months, Humacyte insiders have sold 10,016.77% more of their company's stock than they have bought. Specifically, they have bought $26,975.00 in company stock and sold $2,729,000.00 in company stock. 93.34% of the stock of Humacyte is held by institutions.
What is Humacyte's (Huma) stock symbol?
View all of HUMA's competitors. What is Humacyte's stock symbol? Humacyte trades on the NASDAQ under the ticker symbol "HUMA." Who are Humacyte's major shareholders? Humacyte's stock is owned by many different retail and institutional investors.
Will Humacyte get $255 million from the SPAC?
The SPAC is run by Rajiv Shukla. That's the same person that brought DermTech public through the SPAC, so he's got experience with this process. Humacyte will get $255 million at closing, up to $100 million from the SPAC.
Who buys Huma stock?
HUMA stock was acquired by a variety of institutional investors in the last quarter, including York Capital Management Global Advisors LLC, Monashee Investment Management LLC, CVI Holdings LLC, LPL Financial LLC, Citadel Advisors LLC, Morgan Stanley, Geode Capital Management LLC, and Eudaimonia Partners LLC.
Is humacyte a publicly traded company?
Representatives from Durham-based regenerative medicine company Humacyte got the chance to ring the August 30, 2021 closing bell at the Nasdaq stock exchange, signifying completion of its business combination with Alpha Healthcare Acquisition Corp. (AHAC).
Is humacyte a good stock to buy?
The consensus among 5 Wall Street analysts covering (NASDAQ: HUMA) stock is to Strong Buy HUMA stock.
About Humacyte Stock
Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products called human acellular vessels (HAV) for regenerative medicine and vascular surgery applications. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.
Investors
Gett, WeLab, ironSource, Deezer, Humacyte, TangoMe, Selina, Yotpo, Sentient Technologies, DigitalOcean
Press
EquityZen helps investors to access private companies and their employees to sell shares.
3.5 Analyst's Opinion
Humacyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Is Humacyte a buy right now?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Humacyte stock. View analyst ratings for Humacyte or view top-rated stocks.
What price target have analysts set for HUMA?
4 analysts have issued 1 year price objectives for Humacyte's shares. Their forecasts range from $16.00 to $19.00. On average, they expect Humacyte's stock price to reach $17.25 in the next twelve months.
Who are some of Humacyte's key competitors?
Some companies that are related to Humacyte include Bavarian Nordic A/S (BVNRY), Kymera Therapeutics (KYMR), Adaptive Biotechnologies (ADPT), Valneva (VALN), Exscientia (EXAI), Recursion Pharmaceuticals (RXRX), Vericel (VCEL), NanoString Technologies (NSTG), Revolution Medicines (RVMD), Allogene Therapeutics (ALLO), Krystal Biotech (KRYS), Alector (ALEC), Instil Bio (TIL), iTeos Therapeutics (ITOS) and Atara Biotherapeutics (ATRA). View all of HUMA's competitors..
Who are Humacyte's major shareholders?
Humacyte's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.36%), Geode Capital Management LLC (0.59%), Monashee Investment Management LLC (0.39%), Diameter Capital Partners LP (0.29%), Charles Schwab Investment Management Inc. (0.29%) and LPL Financial LLC (0.23%).
Which institutional investors are selling Humacyte stock?
HUMA stock was sold by a variety of institutional investors in the last quarter, including Diameter Capital Partners LP, Monashee Investment Management LLC, Maven Securities LTD, Susquehanna International Group LLP, Citadel Advisors LLC, PEAK6 Investments LLC, and Philadelphia Trust Co..
Which institutional investors are buying Humacyte stock?
HUMA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Charles Schwab Investment Management Inc., Northern Trust Corp, LPL Financial LLC, Swiss National Bank, Endowment Wealth Management Inc., and Cubist Systematic Strategies LLC. View insider buying and selling activity for Humacyte or or view top insider-buying stocks..
Signals & Forecast
A buy signal was issued from a pivot bottom point on Friday, January 28, 2022, and so far it has risen 19.14%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Support, Risk & Stop-loss
On the downside, the stock finds support just below today's level from accumulated volume at $5.22 and $5.03. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Humacyte, Inc. finds support just below today's level at $5.22.
Is Humacyte, Inc. stock A Buy?
Humacyte, Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
Insiders are very positive buying more shares than they are selling in Humacyte, Inc
In the last 57 trades there were 69.44 million shares bought and 600 thousand shares sold. The last trade was done 60 days ago by Niklason Laura E who sold 75 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Humacyte (NASDAQ:HUMA) Price Target and Consensus Rating
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Price Target Consensus
Sign-up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
Analyst Ratings By Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Average Share Price and Price Target by Month
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
Humacyte (NASDAQ:HUMA) Analyst Ratings Frequently Asked Questions
According to the issued ratings of 4 analysts in the last year, the consensus rating for Humacyte stock is Buy based on the current 4 buy ratings for HUMA. The average twelve-month price target for Humacyte is $17.25 with a high price target of $19.00 and a low price target of $16.00. Learn more on HUMA's analyst rating history